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Claudio G. Brunstein,1,2, Harriet Noreen,3 Todd E. DeFor,1 David Maurer,3
Jeffrey S. Miller,1,2 John E. Wagner1,4Recent registry data suggest that host-versus-graft alloreactions mediated by anti-donor HLA antibodies in
recipients of adult allogeneic hematopoietic stem cells or single-unit umbilical cord blood (UCB) contribute
to the risk of graft failure. The present study evaluated the impact of anti-HLA antibodies on engraftment and
unit predominance in 126 double-UCB (dUCB) recipients. Eighteen dUCB recipients were identified with at
least 1 of 2 UCB units recognized by anti-HLA antibodies directed against donor-directed HLA-specific an-
tibodies (DSAs). Overall, 9 of 12 patients who had DSAs against 1 of the 2 UCB units composing the graft and
5 of 6 patients who had DSAs against both units engrafted. The cumulative incidence of engraftment was sim-
ilar in patients with and without DSAs (83% vs 78%). Thus, our data do not support a negative effect of anti-
HLA antibodies on engraftment, at least in the setting of cyclosporine and mycophenolate mofetil and the
conditioning regimens used at the University of Minnesota, and argue against routine screening for use in
graft selection before dUCB transplantation. Further studies are needed to fully understand the value of
anti-HLA antibody testing in dUCB graft selection and its impact on transplantation outcomes.
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The presence of donor-directed HLA-specific
antibodies (DSAs) has long been associated with
an increased risk of graft failure in solid organ
transplantation [1]. Recent reports indicate that graft
failure is associatedwith the presence ofDSAs in recip-
ients of related haploidentical [2] and unrelated adult
donor hematopoietic cell transplantation (HCT) [3],
aswell as single umbilical cord blood (UCB) transplan-
tation [4,5]. These data suggest that that antibody
screening is needed for optimal donor and UCB unit
selection.
For more than a decade, the use of 2 partially HLA-
matchedUCBunits, referred to as doubleUCB (dUCB)
transplantation, has helped extend the use of this stem
cell source to adults and larger adolescents for whom
an adequate single UCB unit is not available. Nonethe-
less, the rate of neutrophil recovery and hematopoietic1Blood and Marrow Transplantation Program; 2Depart-
of Medicine; 3Immunology/Histocompatibility Labora-
and 4Department of Pediatrics, University of Minnesota.
isclosure: See Acknowledgments on page 1707.
dence and reprint requests: Dr. Claudio G. Brunstein,
rtment of Medicine, Mayo Mail Code 480, 420 Delaware
, SE, Minneapolis, MN, 55455 (e-mail: bruns072@umn.
arch 16, 2011; accepted April 23, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.04.013engraftment is suboptimal [6,7]. The median time to
neutrophil recovery is 26 days, with a risk of graft
failure ranging from 5% to 15% [6,7]. Reasons for
graft failure are likely multifactorial and include the
frequent use of grafts that are mismatched at 4 of 6
HLA loci and/or have low but acceptable cell
doses. Because the presence of relevant DSAs also
may increase the risk of graft failure after UCB
transplantation, we evaluated whether DSAs present
in the recipient before dUCB transplantation
could predict risk of overall engraftment or unit
predominance after transplantation.PATIENTS AND METHODS
Study Design
This retrospective cohort study included dUCB
transplant recipients treated at the University of Min-
nesota Blood and Marrow Transplantation Clinic be-
tween 2004 and 2009. Only patients with
cryopreserved sera collected before dUCB transplan-
tation and available for anti-HLA antibody analysis
were included in the study. The cohort was divided
into 2 categories based on exposure to DSAs directed
against 1 or both of the donor UCB units. Control
subjects were defined as patients exposed to ‘‘irrele-
vant’’ anti-HLA antibodies not directed against either
of the UCB units or patients testing negative for all of
the anti-HLA antibodies. Demographic and engraft-
ment data were collected prospectively and recorded
Table 1. Patient and Transplantation Characteristics
Total patients, n 126
Age, years, median (range) 45 (18-68)
Male sex, n (%) 72 (57%)
Previous autologous transplantation, n (%) 25 (20%)
Disease, n (%)
Acute leukemia 75 (59%)
CML/MDS 16 (13%)
Lymphoid malignancy 27 (21%)
Other 8 (7%)
High-risk disease, n (%) 78 (62%)
Graft-versus-host disease prophylaxis, n (%)
CSA/MMF 124 (98%)
CSA ± MTX/MP 2 (2%)
Myeloablative conditioning, n (%) 44 (35%)
HLA disparity, n (%)
4/6, 4/6 UCB 38 (30%)
4/6, 5/6 UCB 25 (20%)
4/6, 6/6 UCB 1 (1%)
5/6, 5/6 UCB 44 (35%)
5/6, 6/6 UCB 6 (5%)
6/6, 6/6 UCB 12 (10%)
Infused cell doses, median (range)
Nucleated cells, 107/kg 3.8 (2-5.9)
CD34+ cells,  105/kg 4.6 (1.1-13.7)
CD3+ cells,  105/kg 140 (50-310)
Survival, years, median (range) 2.1 (1.0-4.1)
CML indicates chronic myelogenous leukemia; CSA, cyclosporine A;
MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MP,
methylprednisolone; MTX, methotrexate.
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For the purpose of this study, donor engraftment
was defined as $3 consecutive days with an absolute
neutrophil count (ANC) $500/mL in the presence of
$5% chimerism. Graft failure was defined as failure
to achieve an ANC $500/mL or\5% chimerism by
day 142 posttransplantation. Long-term donor pre-
dominance was defined as the UCB unit with $70%
chimerism at day 1100 or beyond [8]. All patients re-
ceived treatment with transplantation protocols ap-
proved by the University of Minnesota’s Institutional
Review Board and provided written informed consent
according to the principles of the Declaration of
Helsinki.
HLATyping and Antibody Determination
All patients and donors were molecularly HLA
typed for HLA-A, -B, -C, -DRB1/3/4/5, and
-DQB1 at high resolution (allele level). Molecular
HLA typing was performed by reverse sequence-
specific oligonucleotide probes (LABType SSO;
One Lambda, Canoga Park, CA) and by sequence-
based typing (AlleleSEQR HLA SBT; Abbott
Molecular, Canoga Park, CA). Stored plasma samples
were tested retrospectively for the presence of anti-
HLA antibody directed against an HLA-A, -B, -C,
-DRB1/3/4/5, or -DQB1 antigen on either UCB
unit. Because the UCB units were not typed at
HLA-DPB1, we were unable to consider that locus.
HLA antibody specificities were determined by solid
phase, single-antigen bead technology using sequen-
tial testing, first with LABScreen Mixed Antigen
(One Lambda) and then with single antigen assays
if samples were positive with the LABScreen. A pos-
itive test for an anti-HLA antibody was defined as an
increase in mean fluorescence intensity (MFI) of
$500 above the negative control. To verify specific-
ity, each lot of reagents was validated against positive
patient samples and standard sera. In addition, in
each analytic run, 2 standard sera samples of known
specificity and antibody strength from highly sensi-
tized patients were included as positive controls.
Statistical Analysis
Descriptive statistics were analyzed to evaluate
patient demographic characteristics and frequency
of DSAs. Although we tested for antibodies to
high-expression and low-expression loci, we made
no distinction between the 2 in the analysis. The cu-
mulative incidence of engraftment was estimated by
treating early death (ie, death before day 21 posttrans-
plantation) as a competing risk [9]. The proportional
hazards model of Fine and Gray was used to assess
the independent effect of anti-HLA antibodies on en-
graftment, controlling for the CD3 dose (by quartile)and HLA match (match vs mismatch) [10]. All factors
were tested for proportional hazards before being in-
cluded in the regression models. Analyses were per-
formed using SAS 9.2 (SAS Institute, Cary, NC) and
R 2.4 (http://cran.r-project.com).RESULTS
Patient Characteristics and Anti-Donor HLA
Alloreactivity
A total of 297 patients received a dUCB transplant
between 2004 and 2009. Of these, 126 patients had
stored plasma available for retrospective testing for
the presence of anti-HLA antibodies. The demo-
graphic characteristics of these patients are summa-
rized in Table 1. Anti-HLA antibodies were present
in 50 of the 126 patients (41%) in our study group. Of
the 50 patients with one or more anti-HLA antibody,
only 12 (24%) had a DSA that targeted 1 UCB unit
(Table 2), and 6 (12%) had a DSA that targeted both
UCB units (Table 3). Among the patients with a DSA
(n 5 18), 12 had an antibody directed against a class I
antigen, and 8 had an antibody directed against a class
II antigen. Only 3 patients had DSAs against both
HLA class I and class II antigens, and all 3 of these pa-
tients had antibodies targeting both UCB units.
Outcomes of UCB Units Targeted by DSAs
Of the 12 patients with a DSA directed against 1 of
2 UCB units, the targeted unit was detectable at day
121 by chimerism assay in 9 patients, contributing
Table 2. Patients with DSA Positivity against 1 of the 2 UCB Units
UPN
(n 5 12) Unit
CD34
( 106/kg)
Anti-HLA Antibody
Specificity for UCB Unit MFI
Chimerism at
Day +21, %
Long-Term
Predominant Unit
Days to
Neutrophil
Recovery* Outcome
4398 1 0.09 DR51 (DRB5*01,02) 685 100 Yes 39 Engrafted
2 0.18 None NA 0 No
4423 1 0.17 A03 (A*03) 12951 97 Yes 18 Engrafted
2 0.06 None NA 0 No
4473 1 0.16 DR14 (DRB1*14) 1044 26 NA 31 Early death
2 0.13 None NA 45 NA
4522 1 0.23 A2 (A*02) 612 0 No 19 Engrafted
2 0.30 None NA 96 Yes
4599 1 0.35 B7 (B*07) 550 100 Yes 14 Engrafted
2 0.30 None NA 0 No
4735 1 0.14 DQ7 (DQB1*03:01) 841 35 No 6 Engrafted; persistent
mixed chimerism†2 0.13 None NA 20 Yes
4755 1 0.21 B7 (B*07) 669 0 NA 5 Graft failure; autologous
recovery2 0.29 None NA 0 NA
4921 1 0.32 A2 (A*02); Cw6 (Cw*06) 3637; 707 48 No 6 Engrafted
2 0.25 None NA 37 Yes
4929 1 1.14 Cw7 (Cw*07) 515 62 No 25 Engrafted
2 0.23 None NA 33 Yes
4930 1 0.15 DR04 (DRB1*04:04) 1337 0 No NA Graft failure
2 0.11 None NA 100 Yes
5003 1 0.28 B35 (B*35) 8308 8 No NA Graft failure
2 0.35 None NA 79 Yes
5057 1 0.11 DR3 (DRB1*03:01,03:02) 536 19 No 25 Engrafted
2 0.50 None NA 77 Yes
UPN indicates unique patient number; NA, not applicable/not available/not achieved.
*>500/mL.
†Although both unit were detected on chimerism assay beyond day +100, the umbilical cord blood unit with no DSA directed was responsible for >70%
of chimerism thus being the predominant one.
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tients, the UCB unit targeted by the DSA predomi-
nated in the long term as the sole chimeric unit in 3
patients and as 1of 2 chimeric units (ie, dual chimerism)
in 1 patient. In 3 patients, the MFI for the DSA was
$3000, with the unit targeted by DSA predominating
in 1 patient who engrafted and persisting short-term
in 1 patient who engrafted with the nontargeted DSA
unit. Graft failure occurred in 2 other patients (one
with MFI $3000) in which the unit targeted by the
DSA never or only minimally contributed to chime-
rism. Six patients had DSAs directed against bothTable 3. Patients with DSAs against Both UCB Units
UPN
(n 5 6) Unit
CD34
( 106/kg) Anti-HLA Antibody Specificity for UCB Unit
4591 1 0.44 A23 (A*23); Cw16 (Cw*16) 9853; 8
2 0.13 Cw5 (Cw*05); DR1
(DRB1*01); DQ5 (DQB1*05)
3797; 1
4626 1 0.28 A1 (A*01) 2644
2 0.27 B44 (B*44) 5417
4693 1 0.46 B60 (B*40:01); Cw7 (Cw*07) 3176; 1
2 0.49 B51 (B*51); Cw15 (Cw*15);
DR4 (DRB1*04)
2130; 5
4777 1 0.18 A2 (A*02) 646
2 0.19 A2 (A*02) 646
4547 1 0.42 DR4 (DRB1*04:01) 660
2 0.31 DR4 (DRB1*04:01) 660
4479 1 0.27 A3 (A*03); Cw3 (Cw*03) 6377; 1
2 0.11 A3 (A*03); Cw3 (Cw*03) 6377; 1
UPN indicates unique patient number; NA, not applicable/not available/not ac
*>500/mL.UCB donor units (Table 3). In 4 patients, only 1 of
the 2 targeted UCB units was detectable by chimerism
assay at day121, whereas in the other 2 patients, both
units coexisted at day 121. Alloreactivity against both
UCB units was particularly intense (MFI $3000) in 4
patients, only 1 of whom experienced graft failure.Effect of Anti-Donor HLA Alloreactivity on
Hematopoietic Recovery
The cumulative incidence of neutrophil recovery
and engraftment for those patients with a DSAMFI
Chimerism at
Day +21, %
Long-Term
Predominant
Unit
Days to
Neutrophil
Recovery* Outcome
89 0 NA 25 Engrafted; early
relapse4,177; 13,618 47 NA
0 No 24 Engrafted
99 Yes
2,354 95 NA NA Graft failure
19; 19,112 0 NA
100 Yes 9 Engrafted
0 No
31 Yes 32 Engrafted
69 No
104 49 Yes 24 Engrafted
474 51 No
hieved.
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was 78% (95% confidence interval [CI], 59%-93%),
with a median time to recovery of 24.5 days (range,
5-39 days). This incidence of recovery was similar to
that in the patients with an irrelevant anti-HLA anti-
body (n 5 32; 84%; 95% CI, 70%-94%; median, 24
days; range, 3-38 days) and those with no antibody at
all (n 5 76; 86%; 95% CI, 85%-94%; median, 19
days; range, 0-42 days; P5 .54). Amultivariate analysis
was performed after adjusting for CD31 cell dose and
HLA matching, factors previously shown to be associ-
ated with unit predominance after dUCB transplanta-
tion [8]. Compared with the patients with DSA (n 5
107), no effect could be discerned for the presence of
DSA on engraftment (relative risk [RR], 0.68; 95%
CI, 0.36-1.29; P 5 .24).DISCUSSION
In the present study, the cumulative incidence of
engraftment seems to be unaffected by the presence
of DSAs in patients undergoing HCT with 2 partially
HLA-matched UCB units. Unlike previous reports in
the context of adult unrelated donor allogeneic HCT
[3] and single-unit UCB transplantation [4], the pres-
ence of DSAs targeting 1 or both UCB donor units
failed to impair engraftment and had no effect on
which unit predominated over the long term. Takana-
shi et al. [4] found an incidence of neutrophil recovery
of only 32% in 20 patients with a DSA directed against
the UCB donor unit. Similar results were reported by
Spellman et al. [3] in the context of adult unrelated do-
nor allogeneic HCT, with donor graft failure occur-
ring in 9 of 10 patients with a DSA, and by Ciurea
et al. [2] in the context of haploidentical transplanta-
tion, with graft failure occurring in 3 of 4 patients
with a DSA. In contrast, the majority of the 18 patients
(78%) in our study achieved long-term engraftment
despite testing positive for a DSA against 1 or both
UCB units. Although it can be speculated that our pa-
tients were protected from graft failure by the presence
of 2 UCB units, this may be the only reason for the dif-
ferences in outcome, given that engraftment was ob-
served in 5 of 6 patients (83%) with antibodies
directed against both units. However, in the first 12 pa-
tients, 7 of 10 evaluable patients (excluding 1 patient
with early death and 1 patient with autologous recov-
ery) demonstrated engraftment with the unit against
which there was no DSA. Thus, even though immedi-
ate rejection of units against which there is a DSA does
not occur, DSA is possibly associated with failure to
engraft long term, favoring engraftment of the unit
against which there is no DSA.
One limitation of the present study is the absence
of analysis for DSA against HLA-DPB1. It remains
possible that antibodies directed against -DP or otherantigens on UCB influence graft failure or unit pre-
dominance. Taken together, our data suggest that
donor-specific HLA alloresponses might not increase
the risk of graft failure in dUCB transplantation.
Whether or not DSA influences unit predominance af-
ter dUCB transplantation remains to be determined in
larger number of patients.
Although screening for DSAs is certainly feasible
[11], it might add to healthcare costs, delay donor ac-
quisition, and lead to the selection of a donor unit
with a lower cell dose or greater HLA mismatch, all
of which are factors proven to negatively impact sur-
vival. We recognize that our small sample size might
have prevented us from detecting the impact of anti-
HLA antibodies, and that different conditioning regi-
mens and posttransplantation immunosuppressive
therapies might have altered our results; nevertheless,
we cannot recommend routine anti-HLA antibody
screening for UCB unit selection in the setting of
dUCB transplantation, because this practice could re-
sult in the selection of less suitable units. Additional
data in larger numbers of patients are needed to estab-
lish a clear association between DSA and graft failure
or unit loss in the setting of dUCB transplantation.ACKNOWLEDGMENTS
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